← board
PHIO
Phio Pharmaceuticals Inc.distress 7/10 · high distress / dilution risk$1.060%today-61% from 52w high
Oncology 1
Lead: cutaneous squamous cell carcinoma
Revenue
pre-revenue
Liquidity
$17M
Runway
1.6 yrs
Shares 1y
+103%
Price & events
-1.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+6.0%
1W
+1.9%
1M
-13.8%
3M
-2.8%
6M
-58.3%
1Y
-71.9%
2Y
-99.5%
5Y
-99.7%
All
Overview
- Market Cap
- $12.31M
- Volume
- 8.65K
- 52 Week Range
- $0.86 – $2.74
- Total Shares
- 11.62M
- Float Shares
- 11.54M
- Short %
- 1.89%
- % Held by Insiders
- 1.93%
- % Held by Institutions
- 10.82%
- RVOL
- 0.01x
- Beta
- 0.81
Pipeline stages · 1 programs
PH-762
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-12-29 | Phase 1 | PH-762 | Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin | 30 | active not recruiting |
Catalyst news & presentations · 8
- first quarter of 2026trial initiationsecondaryPH-762 · Toxicology study commencementSEC 8-K
- 2026-03-30partnershipcGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply.SEC 8-K
- 2025-12-23fda agreementPH-762 · FDA acceptance of nonclinical protocol study designSEC 8-K
- third quarter of 2025enrollment completesecondaryPhase 1PH-762 · Expected completion of enrollment in Phase 1b trial.SEC 8-K
- September 8-10, 2025; presentation on September 10, 2025 at 1:30-2 PM ESTconferencedata presentationsecondaryPhase 1PH-762 · Company presentation at H.C. Wainwright conference with update on Phase 1b trialSEC 8-K
- 2025-07-25partnershipPH-762 · Entered into drug substance development services agreement with U.S. manufacturer for PH-762.SEC 8-K
- podium presentation at SID Annual Meeting on May 10thconferencedata presentationsecondaryPhase 1PH-762 · Podium presentation of trial results to date at Society for Investigative Dermatology Annual Meeting.SEC 8-K
- November 9, 2024conferencedata presentationsecondaryPhase 1PH-762 · Presenting clinical data from Phase 1b trial at SITC 2024SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-02-10HC Wainwright & Co.Buy
- 2025-08-15HC Wainwright & Co.Buy
- 2025-06-25HC Wainwright & Co.Buy
- 2025-04-08HC Wainwright & Co.Buy
- 2025-02-19HC Wainwright & Co.Buy
Competitors — cutaneous squamous cell carcinoma
Recent news
- 2026-07-22Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
- 2026-07-22Phio Pharmaceuticals to Showcase INTASYL siRNA Platform and PH-762 Skin Cancer Therapy at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
- 2026-07-21Phio Pharmaceuticals appoints dermatologist to board By Investing.com - Investing.com South Africa
- 2026-07-21Phio Pharmaceuticals appoints dermatologist to board - Investing.com
- 2026-07-21Phio Pharmaceuticals adds dermatology expert to board - TipRanks
- 2026-07-21Phio Pharmaceuticals adds R. Todd Plott to its Board, joins Governance Committee - TradingView
- 2026-07-21Phio Pharmaceuticals Strengthens Board with Dermatology Expert Dr. R. Todd Plott Amid PH-762 Clinical Progress - Kalkine Media
- 2026-07-21More Than 30 Years in Dermatology: Phio Adds a Director - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.